LeciaVSequistMD

Oncology • Boston, MA

Assistant Professor of Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Sequist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sequist's full profile

Already have an account?

Office
55 Fruit Street Yaw 7b
Hematology/Oncology
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-726-0453

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

MA State Medical License 2001 - 2026
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR Start of enrollment: 2007 Dec 01
Completed
Phase 2
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations Start of enrollment: 2009 Oct 01
Active, not recruiting
Phase 2
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Jul 01
Terminated
Phase 1
Biopsies of Cancer Patients for Tumor Molecular Characterization Start of enrollment: 2010 Feb 01
Completed
Understanding Mechanisms of Acquired Resistance to BIBW2992 Start of enrollment: 2011 Feb 01
Completed
Not Applicable
IPI-504 in NSCLC Patients With ALK Translocations Start of enrollment: 2010 Oct 01
Terminated
Phase 2
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Afatinib With CT and RT for EGFR-Mutant NSCLC Start of enrollment: 2012 Apr 01
Recruiting
Phase 2
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation Start of enrollment: 2013 Jan 01
Active, not recruiting
Phase 2
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Study of TAS-120 in Patients With Advanced Solid Tumors Start of enrollment: 2014 Jul 21
Completed
Phase 1, Phase 2
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Start of enrollment: 2014 Jun 06
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2628 citations
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias-Santagata, Subba R. Digumarthy, Alexa B. Turke
Science Translational Medicine. 2011-03-23
655 citations
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, Maria Gomez-Caraballo, Faria M. Siddiqui
Nature Medicine. 2016-03-01
166 citations
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila
Journal of Thoracic Oncology. 2021-10-01

Journal Articles

Oxford University Press Has Registered This DOI Pre-Publication
R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Lecia V Sequist, Zofia Piotrowska, Clinical Cancer Research
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research
Stress Hormones Promote EGFR Inhibitor Resistance in NSCLC: Implications for Combinations with Β-blockers
Hai Tran, Anil K Sood, John V Heymach, Roy Herbst, Lecia V Sequist, Edward S Kim, Science Magazine
Join now to see all

Lectures

SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Personalized, genotype-directed therapy for advanced non-small cell lung cancer
Sequist LV, Neal JW
http://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-
UpToDate, Wolters Kluwer Health - 2013-02-25

Press Mentions

Who Should Be Screened for Lung Cancer?October 28th, 2024
EGFR and Lung CancerJune 7th, 2024
Promising New AI Can Detect Early Signs of Lung Cancer That Doctors Can't SeeApril 11th, 2023
Join now to see all